GlassScriptPhysician profile
Joel B Mason
NPI 1164539292
$84,141.15
in general payments reported to CMS, 2019-2025
9 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,899 · 2020: $26K · 2021: $5,255 · 2022: $19K · 2023: $19.43 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Travel and Lodging: $644 · Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,900.00 |
| Travel and Lodging | $644.46 |
| Food and Beverage | $279.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $75,928.66 | 2019-2025 | Gattex |
| Shire North American Group INC | $7,807.37 | 2019 | |
| Janssen Biotech, INC. | $221.36 | 2019-2022 | |
| Celgene Corporation | $90.34 | 2021-2022 | |
| Ucb, INC. | $25.67 | 2019-2020 | |
| Genzyme Corporation | $20.84 | 2022 | |
| Abbvie INC. | $17.52 | 2021 | |
| Gilead Sciences, INC. | $15.55 | 2025 | |
| Merck Sharp & Dohme LLC | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.